PL370535A1 - Podstawione pochodne 2-pirymidynylo-6,7,8,9-tetra-hydropirymido [1,2-a] pirymidyn-4-onu i 7-pirymidynylo-2,3-dihydroimidazo [1,2-a] pirymidyn-5 (1H) onu do leczenia zaburzeń neurodegeneracyjnych - Google Patents

Podstawione pochodne 2-pirymidynylo-6,7,8,9-tetra-hydropirymido [1,2-a] pirymidyn-4-onu i 7-pirymidynylo-2,3-dihydroimidazo [1,2-a] pirymidyn-5 (1H) onu do leczenia zaburzeń neurodegeneracyjnych

Info

Publication number: PL370535A1
Authority: PL; Poland
Prior art keywords: pyrimidin; pyrimidinyl; tetrahydropyrimido; dihydroimidazo; derivatives
Prior art date: 2001-09-21

Application number

PL02370535A

Other languages

English (en)

Inventor

Thierry Gallet

Patrick Lardenois

Alistair Lochead

Severine Marguerie

Alain Nedelec

Mourad Saady

Franck Slowinski

Philippe Yaiche

Original Assignee

Sanofi-Aventis

Mitsubishi Pharma Coropration

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-21

Filing date

2002-09-19

Publication date

2005-05-30

2001-09-21 Priority claimed from EP01402431A external-priority patent/EP1295884A1/en

2002-02-28 Priority claimed from EP02290488A external-priority patent/EP1340760A1/en

2002-09-19 Application filed by Sanofi-Aventis, Mitsubishi Pharma Coropration filed Critical Sanofi-Aventis

2005-05-30 Publication of PL370535A1 publication Critical patent/PL370535A1/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Cardiology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Anesthesiology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)

PL02370535A 2001-09-21 2002-09-19 Podstawione pochodne 2-pirymidynylo-6,7,8,9-tetra-hydropirymido [1,2-a] pirymidyn-4-onu i 7-pirymidynylo-2,3-dihydroimidazo [1,2-a] pirymidyn-5 (1H) onu do leczenia zaburzeń neurodegeneracyjnych PL370535A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01402431A EP1295884A1 (en)	2001-09-21	2001-09-21	2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
EP02290488A EP1340760A1 (en)	2002-02-28	2002-02-28	Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives

Publications (1)

Publication Number	Publication Date
PL370535A1 true PL370535A1 (pl)	2005-05-30

Family

ID=26077255

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02370535A PL370535A1 (pl)	2001-09-21	2002-09-19	Podstawione pochodne 2-pirymidynylo-6,7,8,9-tetra-hydropirymido [1,2-a] pirymidyn-4-onu i 7-pirymidynylo-2,3-dihydroimidazo [1,2-a] pirymidyn-5 (1H) onu do leczenia zaburzeń neurodegeneracyjnych

Country Status (24)

Country	Link
US (2)	US7388005B2 (pl)
EP (1)	EP1430056B1 (pl)
JP (2)	JP4570361B2 (pl)
KR (1)	KR100868840B1 (pl)
CN (1)	CN1247586C (pl)
AR (1)	AR036599A1 (pl)
AT (1)	ATE307815T1 (pl)
AU (1)	AU2002342798C1 (pl)
BR (1)	BR0212904A (pl)
CA (1)	CA2457952C (pl)
CY (1)	CY1105553T1 (pl)
DE (1)	DE60206946T2 (pl)
DK (1)	DK1430056T3 (pl)
EA (2)	EA007165B1 (pl)
ES (1)	ES2250721T3 (pl)
HK (1)	HK1091495A1 (pl)
HU (1)	HUP0500332A3 (pl)
IL (2)	IL160397A0 (pl)
MX (1)	MXPA04002632A (pl)
NO (1)	NO329566B1 (pl)
NZ (1)	NZ531244A (pl)
PL (1)	PL370535A1 (pl)
SI (1)	SI1430056T1 (pl)
WO (1)	WO2003027115A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1454909B1 (en) *	2003-03-07	2008-08-20	Sanofi Aventis	8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
EP1557417B1 (en)	2003-12-19	2007-03-07	Sanofi-Aventis	Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives
WO2005070932A2 (en)	2004-01-22	2005-08-04	Amgen Inc.	Substituted heterocyclic compounds and methods of use
ATE482214T1 (de) *	2005-06-14	2010-10-15	Schering Corp	Aspartylproteasehemmer
WO2007025177A2 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP1942879A1 (en)	2005-10-31	2008-07-16	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
JP2009536669A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	アンジオテンシン調節による神経新生
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP1939187A1 (en) *	2006-12-20	2008-07-02	Sanofi-Aventis	Substituted heteroaryl pyridopyrimidone derivatives
EP1992624A1 (en) *	2007-05-16	2008-11-19	Sanofi-Aventis	Heteroarylamide pyrimidone compounds
EP1992620A1 (en) *	2007-05-16	2008-11-19	Sanofi-Aventis	Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992621A1 (en) *	2007-05-16	2008-11-19	Sanofi-Aventis	Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
EP1992625A1 (en)	2007-05-16	2008-11-19	Sanofi-Aventis	Arylamide pyrimidone compounds
EP2085400A1 (en) *	2008-01-29	2009-08-05	Sanofi-Aventis	Substituted heteroarylamide oxazepinopyrimidone derivatives
EP2090579A1 (en) *	2008-01-29	2009-08-19	Sanofi-Aventis	Substituted heteroarylamide diazepinopyrimidone derivatives
EP2085399A1 (en) *	2008-01-29	2009-08-05	Sanofi-Aventis	substituted arylamide oxazepinopyrimidone derivatives
EP2090578A1 (en) *	2008-01-29	2009-08-19	Sanofi-Aventis	Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of GSK3-beta
EP2138498A1 (en) *	2008-06-26	2009-12-30	sanofi-aventis	Substituted tricyclic derivatives against neurodegenerative diseases
EP2138492A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted pyrimidin-4-one derivatives
EP2138495A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives
EP2138494A1 (en) *	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted alkyl pyrimidin-4-one derivatives
EP2138493A1 (en)	2008-06-26	2009-12-30	Sanofi-Aventis	Substituted pyrimidone derivatives
EP2138485A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	Substituted N-Oxide pyrazine derivatives
EP2138488A1 (en)	2008-06-26	2009-12-30	sanofi-aventis	4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8421890B2 (en)	2010-01-15	2013-04-16	Picofield Technologies, Inc.	Electronic imager using an impedance sensor grid array and method of making
WO2015155738A2 (en)	2014-04-09	2015-10-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3865836A (en) *	1972-12-08	1975-02-11	Janssen Pharmaceutica Nv	Bicyclic imidazoles
SU600143A1 (ru) *	1976-12-06	1978-03-30	Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср	Способ получени гетероциклических систем, содержащих бормзамещенный имидазол
JPS63216886A (ja) *	1987-03-05	1988-09-09	Sumitomo Chem Co Ltd	ピリミドピリミジン誘導体およびその製造法
JP2862958B2 (ja) *	1990-06-09	1999-03-03	三協化学株式会社	感熱転写記録用色素
US6153618A (en) *	1996-10-11	2000-11-28	Chiron Corporation	Inhibitors of glycogen synthase 3 kinase
KR100476586B1 (ko) *	1996-12-05	2005-03-18	암젠 인코포레이티드	치환된 피리미딘온 화합물과 이 화합물을 포함하는 제약학적 조성물 및 치료방법
NZ506417A (en) *	1998-02-17	2003-05-30	Tularik Inc	Anti-viral pyrimidine derivatives
JP2003516991A (ja) *	1999-12-17	2003-05-20	カイロンコーポレイション	グリコゲンシンターゼキナーゼ３の二環式インヒビター
FR2804959B1 (fr) *	2000-02-15	2006-04-28	Centre Nat Rech Scient	Utilisation de derives de paullones pour la fabrication de medicaments

2002
- 2002-09-19 EA EA200400236A patent/EA007165B1/ru not_active IP Right Cessation
- 2002-09-19 IL IL16039702A patent/IL160397A0/xx unknown
- 2002-09-19 EP EP02779461A patent/EP1430056B1/en not_active Expired - Lifetime
- 2002-09-19 EA EA200600196A patent/EA009456B1/ru not_active IP Right Cessation
- 2002-09-19 JP JP2003530703A patent/JP4570361B2/ja not_active Expired - Fee Related
- 2002-09-19 DK DK02779461T patent/DK1430056T3/da active
- 2002-09-19 HU HU0500332A patent/HUP0500332A3/hu unknown
- 2002-09-19 MX MXPA04002632A patent/MXPA04002632A/es active IP Right Grant
- 2002-09-19 PL PL02370535A patent/PL370535A1/pl unknown
- 2002-09-19 WO PCT/EP2002/011127 patent/WO2003027115A1/en active IP Right Grant
- 2002-09-19 ES ES02779461T patent/ES2250721T3/es not_active Expired - Lifetime
- 2002-09-19 AU AU2002342798A patent/AU2002342798C1/en not_active Ceased
- 2002-09-19 US US10/490,136 patent/US7388005B2/en not_active Expired - Fee Related
- 2002-09-19 AT AT02779461T patent/ATE307815T1/de active
- 2002-09-19 CN CNB028183398A patent/CN1247586C/zh not_active Expired - Fee Related
- 2002-09-19 DE DE60206946T patent/DE60206946T2/de not_active Expired - Lifetime
- 2002-09-19 SI SI200230235T patent/SI1430056T1/sl unknown
- 2002-09-19 KR KR1020047004138A patent/KR100868840B1/ko not_active IP Right Cessation
- 2002-09-19 NZ NZ531244A patent/NZ531244A/en not_active IP Right Cessation
- 2002-09-19 BR BR0212904-3A patent/BR0212904A/pt not_active Application Discontinuation
- 2002-09-19 CA CA002457952A patent/CA2457952C/en not_active Expired - Fee Related
- 2002-09-20 AR ARP020103540A patent/AR036599A1/es unknown
2004
- 2004-02-15 IL IL160397A patent/IL160397A/en not_active IP Right Cessation
- 2004-03-18 NO NO20041142A patent/NO329566B1/no not_active IP Right Cessation
2006
- 2006-01-09 CY CY20061100020T patent/CY1105553T1/el unknown
- 2006-11-21 HK HK06112764A patent/HK1091495A1/xx not_active IP Right Cessation
2008
- 2008-05-14 US US12/120,496 patent/US7781440B2/en not_active Expired - Fee Related
2010
- 2010-04-21 JP JP2010097989A patent/JP2010189422A/ja active Pending

Also Published As

Publication number	Publication date
CA2457952A1 (en)	2003-04-03
EP1430056A1 (en)	2004-06-23
CN1247586C (zh)	2006-03-29
KR100868840B1 (ko)	2008-11-14
EP1430056B1 (en)	2005-10-26
US20040266793A1 (en)	2004-12-30
JP2005504809A (ja)	2005-02-17
KR20040039390A (ko)	2004-05-10
NO329566B1 (no)	2010-11-15
EA009456B1 (ru)	2007-12-28
DK1430056T3 (da)	2006-02-27
EA007165B1 (ru)	2006-08-25
US7781440B2 (en)	2010-08-24
JP4570361B2 (ja)	2010-10-27
SI1430056T1 (sl)	2006-02-28
CN1556810A (zh)	2004-12-22
ATE307815T1 (de)	2005-11-15
HUP0500332A3 (en)	2009-12-28
WO2003027115A1 (en)	2003-04-03
US20080269257A1 (en)	2008-10-30
DE60206946D1 (de)	2005-12-01
AR036599A1 (es)	2004-09-22
NO20041142L (no)	2004-06-21
CA2457952C (en)	2009-11-10
CY1105553T1 (el)	2010-07-28
DE60206946T2 (de)	2006-07-27
ES2250721T3 (es)	2006-04-16
EA200600196A1 (ru)	2006-08-25
MXPA04002632A (es)	2004-07-08
EA200400236A1 (ru)	2004-10-28
BR0212904A (pt)	2004-10-13
JP2010189422A (ja)	2010-09-02
NZ531244A (en)	2006-06-30
IL160397A0 (en)	2004-07-25
IL160397A (en)	2009-07-20
HUP0500332A2 (hu)	2005-07-28
AU2002342798B2 (en)	2008-01-10
HK1091495A1 (en)	2007-01-19
US7388005B2 (en)	2008-06-17
AU2002342798C1 (en)	2008-09-25

Publication	Publication Date	Title
PL370535A1 (pl)	2005-05-30	Podstawione pochodne 2-pirymidynylo-6,7,8,9-tetra-hydropirymido [1,2-a] pirymidyn-4-onu i 7-pirymidynylo-2,3-dihydroimidazo [1,2-a] pirymidyn-5 (1H) onu do leczenia zaburzeń neurodegeneracyjnych
PL370349A1 (pl)	2005-05-16	Podstawione pochodne 2-pirydynylo-6,7,8,9-tetrahydro-pirymido[1,2-a]pirymidyn-4-onu i 7-pirydynylo-2,3-dihydroimidazo[1,2-a]pirymidyn-5(1H)onu
EP1599482A4 (en)	2008-10-01	PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
IL191960A (en)	2015-11-30	History of imidazo [5,1– a] pyridine and pharmaceutical preparations containing them
IL149026A0 (en)	2002-11-10	PYRAZOLO [4, 3-d] PYRIMIDINE DERIVATIVES
IL151849A0 (en)	2003-04-10	Pyrido [2,3-d] pyrimidine and pyrimido [4,5-d] pyrimidine nucleosides
IL176287A0 (en)	2006-10-05	SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a] PYRIMIDIN-6-ONE DERIVATIVES
AU1224902A (en)	2002-03-13	2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
HUP0402018A3 (en)	2008-06-30	5-amino-7h-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives, their use and pharmaceutical compositions containing them
EP1454909B1 (en)	2008-08-20	8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases
IL170680A0 (en)	2009-02-11	8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
AU2002251546A1 (en)	2003-04-17	Pyrazolo[1,5-A]pyridines and medicines containing the same
ZA200507192B (en)	2007-03-28	Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
IL156536A0 (en)	2004-01-04	Pyrazolo [3,4-d] pyrimidin-4-one derivatives and pharmaceutical compositions containing the same
IL163287A (en)	2009-12-24	HETEROARYL SUBSTITUTED 2 - PYRIDINYL AND 2 - PYRIMIDINYL - 6,7,8,9 - TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
IL175753A0 (en)	2006-09-05	PROCESSES FOR THE PREPARATION OF PYRAZOLO [1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF
AU2003211993A1 (en)	2003-09-04	(1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
SI1480981T1 (sl)	2006-04-30	Derivati 1-(alkil), 1-(heteroaril)alkil- in 1-(aril)alkil)-7-(pirimidin-4-il)-imidazo(1,2-alfa)pirimidin-5(1H)-ona
PL370565A1 (pl)	2005-05-30	Pochodne 5-metoksy-8-arylo[1,2,4]triazolo[1,5-a]pirydyny
PL370067A1 (pl)	2005-05-16	Amid kwasu 8-amino[1,2,4]triazolo[1,5-a]pirydyno-6-karboksylowego
IL155379A0 (en)	2003-11-23	SUBSTITUTED 3,4-DIHYDRO-PYRIMIDO[1,2-a] PYRIMIDINES AND 3,4-DIHYDROPYRAZINO [1,2-a] PYRIMIDINES
IL155380A0 (en)	2003-11-23	SUBSTITUTED 3,4-DIHYDRO-PYRIDO[1,2-a] PYRIMIDINES
AU2002325550A1 (en)	2003-03-18	(1,2,4)triazolo(1,5-a)pyrimidine derivative
AU2002219350A1 (en)	2002-07-24	Pyrazolo(3,4-d)pyrimidine derivatives and their use as purinergic receptor antagonists
IL203601A (en)	2015-03-31	6-Hello-7-History (optionally converted amino) -Pyrazolo [15, - a] pyrimidine and its use in drug preparation

Legal Events

Date	Code	Title	Description
2014-04-30	DISC	Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)